AUS
NZ
UK
CA
USA
IND
Highlights
- Reports $12.8 million net loss amid business restructuring.
- Revenue jumps 10% to $933.9 million, with strong pathology growth.
- Plans special dividend after debt refinancing.
Healius (ASX:HLS), Australia's second-largest pathology group, has reported a $12.8 million net loss for the first half of the financial year. This is a significant shift from the $635.8 million profit recorded in the previous corresponding period, primarily due to the sale of its Lumus Imaging business as part of a broader transformation strategy.
Despite this loss, the company remains focused on streamlining its pathology operations, which are showing promising signs of growth. The division recorded a 7% volume increase in the six months ending December 31, and Healius expects revenue growth in the second half to align with this trend.
However, short-term labor costs impacted earnings, reflecting broader challenges in the healthcare sector. Even with these pressures, the company achieved a 51% surge in underlying earnings before interest and tax (EBIT) to $23.7 million, demonstrating progress in its restructuring efforts.
Revenue for the half-year climbed 10% to $933.9 million, driven by the pathology division’s performance. As of December 30, 2024, the company had $345.3 million in debt, an important factor in its financial strategy moving forward.
A key development in Healius’ transformation plan is the return of proceeds from the Lumus Imaging sale to shareholders through a special dividend. However, this will be executed only after refinancing existing debt facilities. This move aligns with Healius’ commitment to optimizing its balance sheet while delivering value to shareholders.
The company, formerly known as Primary Health Care, continues its transition towards a leaner and more efficient pathology-focused business. With volume and revenue growth expected to remain strong, Healius is positioning itself for a smoother financial trajectory in the upcoming quarters.
Looking ahead, investor sentiment will likely hinge on the company’s ability to manage operational costs, sustain revenue momentum, and execute its debt refinancing strategy. With these factors in play, Healius remains a key player in Australia’s pathology sector, navigating both challenges and growth opportunities.
